brand-logo

  • A first-in-class HIF-PH inhibitor2 that mimics the body's natural response to hypoxia

    OROXAT (roxadustat) is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD)

  • For adult patients with symptomatic anaemia of chronic kidney disease (CKD), OROXAT is like a breath of fresh air, at high altitude

    OROXAT (roxadustat) is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD)

  • A first-in-class HIF-PH inhibitor2 that mimics the body's natural response to hypoxia

    OROXAT (roxadustat) is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD)

Introducting OROXATTM-

A landmark in anaemia of CKD

OROXAT (roxadustat) is the first HIF-PH inhibitor to have gained approval for the treatment of adult patients with symptomatic anaemia associated with CKD. It mimics the body's physiological response to hypoxia at high altitude3 by increasing production of erythropoietin and improving iron availability. This increases haemoglobin levels and red blood cell production, with reduced use of intravenous iron compared with ESA.1 OROXAT is a tablet taken by mouth 3 times a week, on non-consecutive days.1 We invite you to explore this website to discover the difference OROXAT can make to your patients.

  • OROXAT SmPC
  • Sanghani NS, Haase VH. Adv Chronic Kidney Dis. 2019;26(4):253-266.
  • Del Vecchio L, Locatelli F. Expert Opin Investig Drugs. 2018;27(1):125-133.

Any

questions?

Where are you in your journey to explore OROXAT ?

Assess the Challenge

Discover Oroxat

View The Evidence

See How It Is Given

The Patient Perspective

View From The Top

See for yourself

Patients and specialists share their experiences

  • Professor Tamannah Hossain interview
  • Professor Tamannah Hossain interview

Tell me more

News and events

Coming soon ...

Reporting Adverse Events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard  or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to SKF Pharma Ltd. on 0800 783 5018

CKD, chronic kidney disease; DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; HIF-PH, hypoxia-inducible factor prolyl-hydroxylase; NDD, non-dialysis-dependent.